Drug Trial Radar · NCT04278404
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Mar 5, 2020
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Emmes Company, LLC; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Feb 20, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 years, up to 20 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Conditions
- Coronavirus Infection (COVID-19)
- Pulmonary Arterial Hypertension
- Urinary Tract Infections in Children
- Hypertension
- Pain
- Hyperphosphatemia
- Primary Hyperaldosteronism
- Edema
- Hypokalemia
- Heart Failure
- Hemophilia
- Menorrhagia
- Insomnia
- Pneumonia
- Skin Infection
- Arrythmia
- Asthma in Children
- Bronchopulmonary Dysplasia
- Adrenal Insufficiency
- Fibrinolysis; Hemorrhage
- Attention Deficit Hyperactivity Disorder
- Multisystem Inflammatory Syndrome in Children (MIS-C)
- Kawasaki Disease
- Coagulation Disorder
- Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:Drug
The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clearance (CL) or apparent oral clearance (CL/F) as measured by PK samplingTime frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
- Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK samplingTime frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
- Elimination rate constant (ke) as measured by PK samplingTime frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
- Half-life (t1/2) as measured by PK samplingTime frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
- Absorption rate constant (ka) as measured by PK samplingTime frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
- AUC (area under the curve) as measured by PK samplingTime frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
- Maximum concentration (Cmax) as measured by PK samplingTime frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
- Time to achieve maximum concentration (Tmax) as measured by PK samplingTime frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Completed
Arkansas Children's Hospital Research Institute
Little Rock, Arkansas · Completed
University of California, Los Angeles Medical Center
Los Angeles, California · Completed
Lucile Packard Children's Hospital
Palo Alto, California · Recruiting
Colorado University Denver
Aurora, Colorado · Completed
The Children's Hospital Colorado
Aurora, Colorado · Completed
Alfred I. DuPont Hospital for Children
Wilmington, Delaware · Completed
University of Florida Jacksonville Shands Medical Center
Jacksonville, Florida · Completed
Kapiolani Womens and Childrens Medical Center
Honolulu, Hawaii · Completed
Ann and Robert H. Lurie Childrens Hospital of Chicago
Chicago, Illinois · Completed
Ann and Robert H. Lurie Childrens Hospital of Chicago
Chicago, Illinois · Completed
Riley Hospital for Children at Indiana University
Indianapolis, Indiana · Completed
University of Iowa Stead Family Children's Hospital
Iowa City, Iowa · Completed
University of Kansas Medical Center-JG Kidney Institute
Kansas City, Kansas · Completed
University of Louisville Norton Childrens Hospital
Louisville, Kentucky · Completed
Tulane University Health Science Center
New Orleans, Louisiana · Completed
Ochsner Baptist Clinical Trials Unit
New Orleans, Louisiana · Completed
University of Maryland Medical Center
Baltimore, Maryland · Completed
Boston Children's Hospital
Boston, Massachusetts · Completed
Massachusetts General Hospital
Lexington, Massachusetts · Completed
University of Minnesota
Minneapolis, Minnesota · Completed
University of Mississippi Medical Center
Jackson, Mississippi · Completed
Mississippi Center for Advanced Medicine
Madison, Mississippi · Completed
Children's Mercy Hospital
Kansas City, Missouri · Completed
University of Nebraska Medical Center
Omaha, Nebraska · Completed
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire · Completed
University of New Mexico Health Science Center
Albuquerque, New Mexico · Completed
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Completed
Duke University Health System
Durham, North Carolina · Recruiting
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio · Completed
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio · Recruiting
Board of Regents of the University of Oklahoma
Oklahoma City, Oklahoma · Completed
Oregon Health and Science University
Portland, Oregon · Completed
Pennsylvania State University--Hershey Children's Hospital
Hershey, Pennsylvania · Completed
Rhode Island Hospital
Providence, Rhode Island · Completed
Medical University of South Carolina Children's Hospital
Charleston, South Carolina · Completed
University of South Carolina
Columbia, South Carolina · Completed
Avera McKennan Hospital & University Medical Center
Sioux Falls, South Dakota · Completed
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee · Completed
Dell Children's Medical Center of Central Texas
Austin, Texas · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.